Biocon Limited:Hold,Neulasta
类型：投资策略 机构：香港上海汇丰银行有限公司 研究员：香港上海汇丰研究所 日期：2017-08-02
http://www.zdcj.net 点击收藏此报告
From 6 possible late stage players, competition in Neulastabiosimilar narrows to 1-2 players in the near term
CRL and/or cGMP issues hurting most. We look at Form 83issued to facilities of Intas/Apotex and Biocon/Mylan
Biosimilar opportunity exciting but facility clearance is a hurdlenear term; Hold with revised TP of INR370 (from INR355)
相关报告：
热点推荐：
